Greatbatch Sets Up Shop In Singapore: Targets Emerging Markets
Executive Summary
In July, Greatbatch Inc. announced that its QiG Group established a research and development center in Singapore, with a focus on the development of active implantable medical devices, that is, the kinds of devices that are powered by batteries or other sources. Greatbatch thus sets up a regional presence that will help it develop medical devices that address the specific needs of emerging markets in the Asia-Pacific region. The Singapore initiative is also a stake in the ground for Greatbatch’s strategy to remake itself and the medical device industry.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.